According to the present invention, S100A4 protein also known as Mts-1
interferes with the function of Annexin 2 and Annexin2/P11 tetramer by
binding to Annexin 2. The present inventors have demonstrated that
binding of S100A4 with Annaxin 2 modulates angiogenesis by interfering
with Annexin 2 mediated tissue plasminogen activator (tPA) dependant
conversion of plaminogen into plasmin and further conversion of plasmin
into angiostatins. The present invention has further identified that the
S100A4 protein binds to the N-terminal region of Annexin 2. Accordingly,
the present invention discloses peptides and pharmaceutical compositions
thereof and methods of treating cancers and other diseases that involve
angiogenesis, by interfering with the interaction between S100A4 and
Annexin